Protein arginine methyltransferase 5 (PRMT5) catalyzes the transfer of methyl groups from the co-factor S-adenosylmethionine (SAM) to arginine side chains in numerous protein targets. The enzyme plays an important role in different cellular processes, including tumorigenesis. PRMT5 is up-regulated in several human malignancies, including ovarian cancer, leukemia, lymphomas, lung cancer, and breast cancer. Its expression is often correlated with poor patient prognosis. Lead Pharma aims to develop small molecule inhibitors for this key epigenetic regulator.
This project is currently in the lead identification.